Clinical Trial Update: Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 safety and efficacy trial of a new chemotherapy agent for small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Unspecified chemotherapy agent

Snippet

Sponsor: Bayer | Conditions: Small Cell Lung Carcinoma | Phase 2 | Status: TERMINATED